Is PATH a Buy? What to Consider in 2026
Short answer
The bull case for UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation (PATH) rests on Agentic Automation as the Next Growth Layer: UiPath is repositioning itself from an RPA vendor into what it calls a global leader in agentic automation, offering tools including Agent Builder, Agentic Orchestration, and UiPath Maestro for process intelligence. Revenue (FY2026, ended Jan 31, 2026) is ~$1.61 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. Whether PATH is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation (RPA) with AI-powered capabilities including agentic automation, process orchestration, intelligent document processing, and governance tooling. Its core product, the UiPath Platform, enables AI agents, software robots, and human workers to collaborate in coordinated workflows across industries including financial services, healthcare, manufacturing, retail, and the public sector. The company makes money primarily through subscription and cloud software licenses, which generate high gross margins in the 83-85 percent range, supplemented by professional services revenue. ARR, the annualized value of active subscription contracts, is its primary business-health metric and stood at $1.853 billion as of January 31, 2026. UiPath was founded in 2005 in Bucharest, Romania by Daniel Dines and Marius Tarca, originally as a software outsourcing firm before pivoting to RPA. It relocated its headquarters to New York City and went public on the NYSE in April 2021 in one of the largest US software IPOs of that era. Dines, who serves as Founder and Chief Executive Officer, led the company through a period of rapid growth followed by a strategic reset that included executive changes and a renewed focus on operational efficiency. Chief Operating Officer and CFO Ashim Gupta has been credited with driving the cost discipline that produced the company's first full-year GAAP operating profit in fiscal 2026. The company employs approximately 4,000 people globally.
What's the case for buying PATH?
Agentic Automation as the Next Growth Layer
UiPath is repositioning itself from an RPA vendor into what it calls a global leader in agentic automation, offering tools including Agent Builder, Agentic Orchestration, and UiPath Maestro for process intelligence. Enterprises are moving from automation pilots into scaled, production deployments that require a trusted governance and orchestration layer. This transition could expand UiPath's addressable market well beyond traditional RPA if customers choose a unified platform rather than stitching together standalone AI tools.
Re-accelerating Revenue Growth with a Maturing Margin Profile
After a period of single-digit revenue growth, UiPath posted 13 percent full-year revenue growth in FY2026 and 17 percent year-over-year growth in Q1 FY2027, with $418 million in quarterly revenue. Simultaneously, the company achieved its first full-year GAAP operating profit and generated approximately $372 million in free cash flow in FY2026, indicating that revenue growth and profitability can coexist. Non-GAAP gross margins of 85 percent signal meaningful operating leverage as the company scales.
Large Installed Base and High Switching Costs
UiPath has over 8,500 enterprise customers globally and has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for multiple consecutive years, as well as a Leader in Gartner's inaugural Magic Quadrant for Intelligent Document Processing. Its dollar-based net retention rate of 107 percent indicates that existing customers are modestly expanding their spending. Deep workflow integrations across mission-critical enterprise systems create meaningful switching costs and a relatively sticky revenue base.
Balance Sheet Strength and Capital Return
UiPath ended FY2026 with $1.69 billion in cash, cash equivalents, and marketable securities and essentially no debt, giving it substantial financial flexibility. The company authorized a new $500 million stock repurchase program following the completion of a prior $1 billion program, and it has been reducing its share count. A strong balance sheet provides runway for continued R&D investment and tuck-in acquisitions, such as the WorkFusion deal closed in early FY2027, without reliance on external capital markets.
What are the risks to PATH?
The central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. Competition from Automation Anywhere, Blue Prism, and emerging agentic AI startups intensifies pricing pressure and increases customer acquisition costs. UiPath's revenue growth has been inconsistent historically, and approximately 24 percent of its outstanding shares are sold short, reflecting meaningful market skepticism about whether the agentic pivot will translate into durable ARR acceleration. Insider selling, including by founder Daniel Dines, has also weighed on investor sentiment.
How is PATH valued? (as of 2026-06-27)
- Revenue (FY2026, ended Jan 31, 2026): ~$1.61 billion
- Revenue Growth (FY2026 YoY): ~13%
- ARR (as of Jan 31, 2026): ~$1.85 billion
- GAAP Gross Margin (FY2026): ~83%
- Free Cash Flow (FY2026): ~$372 million
- Market Capitalization: ~$5.3 billion
- Trailing P/E Ratio: ~17x
- Forward P/E Ratio: ~12x
- EV/EBITDA: ~32x
- Cash and Marketable Securities: ~$1.69 billion
UiPath's trailing P/E of roughly 17x sits well below the broader US software sector average of approximately 26x, reflecting the market's uncertainty about whether agentic AI tailwinds will translate into sustained double-digit ARR growth. The company's strong gross margin profile of 83 percent and $372 million in FY2026 free cash flow indicate a fundamentally healthy software business, but the stock has declined significantly from its post-IPO highs as growth decelerated and competition intensified. The forward P/E of roughly 12x implies the market is pricing in limited earnings growth, creating a potential valuation gap if the re-acceleration seen in recent quarters proves durable.
How do you decide if PATH is a buy?
Rather than asking whether PATH is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold PATH indirectly through an index or sector ETF before adding more.
For the full picture, see the PATH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about PATH against your real portfolio and see your actual exposure before deciding.
The bottom line on PATH
The bottom line: UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation's story right now is Agentic Automation as the Next Growth Layer, with revenue (fy2026, ended jan 31, 2026) at ~$1.61 billion. If you believe that narrative continues, the call is about sizing PATH sensibly and checking overlap with what you own; if you doubt it (the risk: the central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around PATH with Walnut
Use UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is PATH a good stock to buy right now?
+
The case for UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation right now is Agentic Automation as the Next Growth Layer, with revenue (fy2026, ended jan 31, 2026) at ~$1.61 billion. If you believe that thesis holds, PATH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation do?
+
UiPath builds and sells an integrated enterprise automation platform that combines traditional robotic process automation (RPA) with AI-powered capabilities including agentic autom
What are the main risks of PATH?
+
The central bear case is platform displacement: generative AI and agentic tools embedded into Microsoft 365, ServiceNow, and cloud hyperscaler platforms could allow enterprises to automate complex workflows without a dedicated RPA layer, gradually eroding UiPath's core value proposition. Competition from Automation Anywhere, Blue Prism, and emerging agentic AI startups intensifies pricing pressure and increases customer acquisition costs. UiPath's revenue growth has been inconsistent historically, and approximately 24 percent of its outstanding shares are sold short, reflecting meaningful market skepticism about whether the agentic pivot will translate into durable ARR acceleration. Insider selling, including by founder Daniel Dines, has also weighed on investor sentiment.
What does UiPath do?
+
UiPath builds an enterprise automation platform that combines robotic process automation (RPA) with AI capabilities including agentic automation, intelligent document processing, process orchestration, and governance tooling. Its software enables AI agents, software robots, and human workers to collaborate in coordinated workflows. It serves large enterprises across financial services, healthcare, manufacturing, retail, and government sectors globally.
Is PATH a good stock to buy right now?
+
That depends on your investment horizon, risk tolerance, and existing portfolio exposure. UiPath has re-accelerating revenue growth, its first full-year GAAP profitability, and a trailing P/E well below its software peers, which some see as attractive. However, the stock has declined sharply, short interest is elevated at roughly 24 percent of shares outstanding, and competition from Microsoft and ServiceNow poses real structural risks. Neither outcome is certain.
Does PATH pay a dividend?
+
No. UiPath does not currently pay a dividend and has not historically done so. The company has instead used its cash to fund R&D, make acquisitions, and repurchase shares, including a new $500 million buyback program authorized after FY2026. Investors seeking income from automation-sector exposure would need to look elsewhere or hold UiPath within a broader dividend-generating portfolio.
Who are UiPath's main competitors?
+
UiPath's primary competitors include Microsoft Power Automate, which benefits from deep Microsoft 365 and Azure integration; Automation Anywhere, the other major pure-play RPA vendor; and enterprise platform vendors like ServiceNow and Salesforce that are embedding native automation and AI agent capabilities. Blue Prism, Appian, and newer agentic AI startups also compete for specific enterprise segments.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell PATH; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.